Repligen Launches Cutting-Edge Chromatography Resins
Repligen Corporation, a leader in bioprocessing technology, has recently launched three groundbreaking chromatography resins that are set to revolutionize workflows in new modalities. The newly unveiled AVIPure HiPer™ AAV9 and AVIPure HiPer™ AAV8 affinity resins, along with the HiPer™ QA anion exchange resin, are specifically engineered to support the growing needs of gene therapy developers.
Enhancing Bioprocessing Efficiency
These innovative HiPer resins utilize the advanced Tantti™ DuloCore™ base bead technology. This base technology is pivotal for delivering superior performance crucial for the development of new modalities such as viral vectors. By using these resins, gene therapy manufacturers can enhance product development timelines significantly, improve the stability of therapeutic molecules, and create economies of scale, all of which contribute to a more expedient route to market.
Addressing Market Demands
As the biopharmaceutical landscape evolves, there is a palpable momentum towards new modalities. Repligen is keenly aware of this shift and is persistently focused on equipping clients with state-of-the-art tools necessary to thrive in an increasingly competitive environment. The introduction of these new resins underscores the company's dedication to advancing process productivity and solidifying its leading position ahead of major chromatography resin launches anticipated in the near future.
Expert Insights on New Products
Umay Saplako?lu, Vice President of Proteins and Incubator at Repligen, articulates the significance of these resins: “Our focus is on developing solutions that are not only scalable but also deliver high performance. The introduction of our AAV8 and AAV9 resins, along with the HiPer QA anion-exchange resin, exemplifies our commitment to providing tools that meet the complex challenges faced by today's biotherapeutic manufacturers.”
Innovation at Its Core
What sets Repligen apart is its unwavering commitment to innovation. The new chromatography resins have been designed to address the complex workflows encountered during the development of biotherapeutics. Each product is crafted to ensure that users can benefit from faster processing times without compromising on quality or efficiency.
About Repligen Corporation
Founded to inspire advances in bioprocessing, Repligen Corporation is a notable player in the global life sciences market. The company specializes in developing and commercializing highly innovative bioprocessing technologies and systems aimed at streamlining the manufacture of biological pharmaceuticals. With a focus on filtration, fluid management, chromatography, process analytics, and proteins, Repligen serves biopharmaceutical drug developers and contract organizations on a global scale.
Global Reach and Commitment
Headquartered in Waltham, Massachusetts, Repligen operates multiple manufacturing sites in the U.S. and has additional facilities across Europe, including Estonia, France, Germany, Ireland, the Netherlands, and Sweden. This extensive footprint not only allows for localized support but also demonstrates Repligen’s commitment to global bioprocessing innovation.
Frequently Asked Questions
What are the new chromatography resins introduced by Repligen?
Repligen has launched the AVIPure HiPer™ AAV9, AVIPure HiPer™ AAV8 affinity resins, and HiPer™ QA anion exchange resin.
How do the new resins improve bioprocessing?
These resins enhance processing times, molecule stability, and overall economic efficiency, offering faster paths to market for gene therapy manufacturers.
What technology underpins the new chromatography resins?
The new resins are built using the advanced Tantti™ DuloCore™ base bead technology, which optimizes their performance for emerging modalities.
What is Repligen's primary market focus?
Repligen primarily focuses on biopharmaceutical manufacturers and contract development organizations, providing them with innovative bioprocessing solutions.
Where is Repligen Corporation located?
Repligen is headquartered in Waltham, Massachusetts, with manufacturing facilities in both the U.S. and Europe.
